Business
Editas Medicine Reports on Recent Progress at J.P. Morgan Healthcare Conference
Provides updates on advancements in in vivo and engineered cell medicine programs Details timeline to filing an IND for EDIT-301 for the treatment of sickle
About this update from Editas Medicine, Inc.
[{"type":"text","content":"Provides updates on advancements in in vivo and engineered cell medicine programs\n Details timeline to filing an IND for EDIT-301 for the treatment of sickle cell disease CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- In a presentation to investors on Wednesday, January 15, 2020, at 10:30 a.m. PST at the 38th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (Nasdaq: EDIT) President and CEO Cynthia Collins will discuss the Company’s progress on developing in vivo and engineered cell medicines and building the leading genomic medicine company. In her remarks, Ms. Collins will discuss several components of the Company’s progress and detail timelines, including plans to: Dose the first patient in the Brilliance clinical trial of EDIT-101 (AGN-151587) for the treatment of Leber congenital amaurosis 10 (LCA10) in the first quarter of 2020 and complete dosing the adult low- and mid-dose cohorts by the end of the year;File an Investigational New Drug (IND) application for EDIT-301 for the treatment of sickle cell disease by the end of 2020;Initiate IND-enabling studies for engineered natural killer (NK) cell medicine for the treatment of solid tumors;Advance alpha-beta T cell medicines in partnership with Bristol-Myers Squibb Company;Establish in vivo preclinical proof-of-concept for an engineered iPSC-derived NK (iNK) cell medicine; andEstablish in vivo preclinical proof-of-concept for a neurological indication. “We are entering 2020 with strong momentum and a strategic focus on driving our pipeline of in vivo CRISPR and engineered cell medicines forward with the ultimate vision of developing differentiated, transformational medicines for people living with serious diseases,” said Collins. “Our team is making history with the first ever clinical trial of an in vivo CRISPR medicine, advancing our broader pipeline of in vivo CRISPR medicines, and progressing our engineered cell medicines for hemoglobinopathies and cancers. With our recent achievements, I expect our clinical pipeline to yield a robust and sustainable portfolio of differentiated, transformative medicines and ensure the Company’s long-term growth.” In addition to sharing details on the Company’s progress and timelines, Ms. Collins will also discuss recent achievements and outlook for 2020: Progress in In Vivo CRISPR Medicines EDIT-101 is on track to be ...